DIAGNOS Announces Changes to its Board of Directors

DIAGNOS Inc. ("DIAGNOS" or the "Corporation") (TSX VENTURE:ADK), a leader in
healthcare technical services including screening, software and algorithm
development, data analysis and image processing, is pleased to announce the
appointment of Mr. Lloyd M. Segal and Mr. Michael Singer as Directors of the
Corporation following the resignations of Mr. Rich Baxter and Mr. Bruno Maruzzo.


The Board wishes to thank Mr. Baxter and Mr. Maruzzo for their important
contribution to DIAGNOS. 


Mr. Segal is Managing Partner at Persistence Capital Partners ("PCP"), Canada's
only private equity fund exclusively focused on high-growth opportunities in
Canadian healthcare. Mr. Segal is responsible for all aspects of PCP's
investments from sourcing, evaluating and executing on investment opportunities,
to managing existing investments. Mr. Segal has previously served as a director
of several public and private corporations in the U.S. and Canada.


Mr. Singer is a Pharmaceutical industry Chief Financial Officer and consultant
with senior level experience in both public and private life science and
innovative technology companies. Prior to joining DIAGNOS, Mr. Singer served as
Chairman of the board of Directors of Warnex Inc. ("Warnex"). On July 8th, 2014,
Warnex was amalgamated with a wholly-owned subsidiary of DIAGNOS.


About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a
mission to commercialize technologies combining contextual imaging and
traditional data mining thereby improving decision making processes. DIAGNOS
offers products, services, and solutions to clients in a variety of fields
including healthcare and natural resources.


Neither the TSX Venture Exchange nor its Regulation Service Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


For further information on DIAGNOS, please visit our website at www.diagnos.com
or the SEDAR website at www.sedar.com.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Andre Larente
President
(450) 678-8882 ext 224

Diagnos (TSXV:ADK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024